Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. AAPL
4. CHYM
5. USO
6. QCOM
7. IRT
8. ASO
9. LAES
10. NTHI

Go back to Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon
SAREPTA THERAP (NASDAQ: SRPT) Delayed: 22.20 +1.26 (6.02%)
Previous Close $20.94    52 Week High $63.73 
Open $20.81    52 Week Low $8.00 
Day High $23.22    P/E N/A 
Day Low $20.63    EPS $-5.69 
Volume 2,809,981